Evidence map›Paper›PMID 39623440›Full record

ArticleAddiction science & clinical practice2024

Regaining control over alcohol intake but not abstinence on disulfiram medication, as a harm reduction approach: 2 case reports.

Max Schallenberg, Maximilian Pilhatsch, Johannes Petzold, Diana Vogel-Blaschka, Ulrich S Zimmermann, Maik Spreer

Abstract readCase Reports
In one paragraph

Article in Addiction science & clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Max SchallenbergDepartment of Psychiatry and Psychotherapy, Carl Gustav Carus Faculty of Medicine, Carl Gustav Carus University Hospital Dresden, Dresden University of Technology, Dresden, Germany. max.schallenberg@mailbox.tu-dresden.de.ORCID 0009-0002-7472-9649
Maximilian PilhatschDepartment of Psychiatry and Psychotherapy, Carl Gustav Carus Faculty of Medicine, Carl Gustav Carus University Hospital Dresden, Dresden University of Technology, Dresden, Germany.ORCID 0000-0003-4323-3309
Johannes PetzoldDepartment of Psychiatry and Psychotherapy, Carl Gustav Carus Faculty of Medicine, Carl Gustav Carus University Hospital Dresden, Dresden University of Technology, Dresden, Germany.ORCID 0000-0003-4163-9014
Diana Vogel-BlaschkaDepartment of Psychiatry and Psychotherapy, Elblandklinikum Radebeul, Radebeul, Germany.ORCID 0000-0002-9674-3874
Ulrich S ZimmermannDepartment of Psychiatry and Psychotherapy, Carl Gustav Carus Faculty of Medicine, Carl Gustav Carus University Hospital Dresden, Dresden University of Technology, Dresden, Germany.
Maik SpreerDepartment of Psychiatry and Psychotherapy, Carl Gustav Carus Faculty of Medicine, Carl Gustav Carus University Hospital Dresden, Dresden University of Technology, Dresden, Germany.ORCID 0000-0001-8436-8520

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlcohol use disorder (AUD) poses severe health risks, yet many affected individuals opt out of complete abstinence. Therefore, harm reduction strategies have become more prominent in treatment guidelines for AUD. Our two case reports illustrate how disulfiram, initially intended to enforce abstinence, was repurposed to support reduced drinking. CASE PRESENTATIONS: A 41-year-old patient with a history of severe AUD successfully reduced his alcohol consumption to a low-risk level by leveraging the effects of the disulfiram-alcohol aversive reaction. Another patient, a 63-year-old woman with long histories of AUD and major depressive disorder, experienced fewer depressive episodes and hospitalizations with disulfiram therapy despite periodically intentional discontinuation of medication.

conclusionIndividualized treatment strategies are critical in optimizing outcomes for patients with AUD. Continuous disulfiram therapy, despite its limitations in directly reducing alcohol intake, might offer a new avenue for harm reduction in exceptional cases even if alcohol consumption continues. The cases suggest that maintaining therapy, aiming at reduced drinking, can enhance the therapeutic alliance and help manage comorbid conditions. Regular medical monitoring is essential for safety and efficacy, warranting further study of possible long-term consequences and psychotropic effects of elevated acetaldehyde levels related to the disulfiram-alcohol interaction.

Indexed as

Alcohol DeterrentsAlcoholismDisulfiramHarm ReductionAdultAlcohol AbstinenceAlcohol DrinkingFemaleHumansMajor Depressive DisorderMaleMiddle AgedAlcohol DeterrentsDisulfiramAlcohol dependence treatmentAlcohol use disorderDisulfiramHarm reductionReduced drinking

Identifiers

PMID39623440
PMCPMC11610367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.